Welcome to our dedicated page for ALLURION TECHNOLOGIES news (Ticker: ALUR), a resource for investors and traders seeking the latest updates and insights on ALLURION TECHNOLOGIES stock.
Allurion Technologies, Inc. (NYSE: ALUR) is a medical device company focused on metabolically healthy weight loss through its Allurion Program and Allurion Smart Capsule. This news page aggregates company press releases and third-party coverage so readers can review how Allurion communicates progress on its weight-loss platform, clinical studies, regulatory milestones, and capital markets activity over time.
Company announcements frequently highlight developments related to the Allurion Smart Capsule, described as the world’s first and only swallowable, Procedureless™ gastric balloon for weight loss, and the Allurion Virtual Care Suite, which includes the Allurion Mobile App, Allurion Insights with the Iris AI Platform, and the Allurion Connected Scale. News items also cover the company’s strategic focus on metabolically healthy weight loss, including combination approaches with low-dose GLP-1 therapies and efforts to maintain or increase lean body mass in patients with overweight and obesity.
Investors and observers can use this page to follow updates on clinical evidence, such as peer-reviewed publications and case series involving the Smart Capsule, lifestyle interventions, and GLP-1 combination therapy. Allurion’s releases describe multicenter studies, case-controlled analyses, and outcomes related to weight reduction, fat mass loss, visceral fat loss, and body composition.
In addition, Allurion’s news flow includes regulatory and financial milestones, including progress in the FDA PMA process for the Allurion Smart Capsule, FDA inspections, Day-100 meetings, private placements of equity and warrants, and transactions to exchange outstanding debt for convertible preferred equity. Readers interested in ALUR news can consult this feed to see how the company reports on its operating strategy, financial results, and key risk disclosures over time.
Allurion Technologies (NYSE: ALUR), an anti-obesity focused company, has scheduled its fourth quarter 2024 financial results announcement for March 26, 2025. The company will host a conference call and webcast at 8:30 AM ET on the same day to discuss the results and provide a business update.
Investors can access the conference call via phone at (888) 330-3417 (domestic) or +1 646 960 0804 (international) using Conference ID 1905455. A live audio webcast will be available in the Events section of Allurion's Investor Relations website. A replay will be accessible by phone using Access Code 1905455 and through the archived webcast on the company's IR website.
Allurion Technologies (NYSE: ALUR) has received two new U.S. patent notifications from the USPTO for its next-generation weight loss device. The patents, scheduled to issue on March 11, 2025, cover an enhanced valve for balloon filling and an innovative balloon opening mechanism, providing protection through April 2043.
The company's patent portfolio now includes 22 U.S. patents and 64 global patents. The Allurion Program combines their swallowable, procedure-less gastric balloon with the Allurion Virtual Care Suite, featuring a Mobile App, Connected Scale, and Iris AI Platform for healthcare providers.
Clinical results show patients typically lose 10-15% of their total body weight, with some studies demonstrating increased muscle mass. The company plans to conduct new clinical trials combining the Allurion Balloon with GLP-1 therapy.
Allurion Technologies (NYSE: ALUR), a company focused on ending obesity, has announced its participation in two major upcoming investor conferences. Dr. Shantanu Gaur, Founder and CEO, will present at the 45th Annual TD Cowen Healthcare Conference in Boston on March 3, 2025, at 9:10 a.m. ET, where he will also conduct one-on-one investor meetings.
Additionally, Dr. Gaur will host individual investor meetings at the 37th Annual Roth Conference in Dana Point, California, from March 16-18, 2025. Investors can access the presentation webcast through the Events & Presentations section of Allurion's investor relations website.
Allurion Technologies (NYSE: ALUR) has successfully closed its previously announced financing round, raising approximately $6.1 million through multiple transactions. The company completed a registered direct offering of 900,000 common stock shares at $5.23 per share, along with warrants for 1,800,000 additional shares. Additionally, a concurrent private placement with Leavitt Equity Partners included 267,686 shares and warrants for 535,372 shares at the same price.
The warrants have an exercise price of $5.23 per share and will become exercisable immediately following stockholder approval, with a five-year expiration term. Roth Capital Partners served as the exclusive placement agent for both transactions. The company plans to use the proceeds to fund clinical trials exploring the combination of the Allurion Balloon with GLP-1 therapy, focusing on muscle mass and long-term GLP-1 adherence, as well as for working capital and general corporate purposes.
Allurion Technologies (NYSE: ALUR) has announced a financing deal to raise approximately $6.1 million in gross proceeds through a combination of offerings. The company will sell 900,000 shares of common stock at $5.23 per share in a registered direct offering and issue warrants for 1,800,000 additional shares in a concurrent private placement.
Additionally, the company entered into a subscription agreement with Leavitt Equity Partners for 267,686 shares and warrants for 535,372 shares at the same price point. The warrants have an exercise price of $5.23 per share and will be exercisable upon stockholder approval, expiring five years after approval.
The proceeds will fund Allurion's clinical pipeline testing the combined effects of the Allurion Balloon and GLP-1 therapy on muscle mass and long-term GLP-1 adherence, working capital, and general corporate purposes. The closing is expected around February 20, 2025.
Allurion Technologies (NYSE: ALUR) has announced plans to initiate a clinical study combining the Allurion Balloon with GLP-1 agonists to treat obesity. The study aims to demonstrate improved long-term tolerability and adherence to GLP-1 therapy using lower doses.
Current data shows that 30% of patients discontinue GLP-1 therapy within the first month, and 58% stop before achieving meaningful health benefits due to side effects, dose escalation requirements, and cost. Previous research, published in Obesity Surgery, demonstrated enhanced weight loss and co-morbidity resolution at four months when combining the Allurion Balloon with oral semaglutide compared to balloon therapy alone.
Allurion Technologies (NYSE: ALUR) has received clearance from ANSM, the French regulatory authority, to resume sales of the Allurion Balloon in France, historically their top-performing market representing approximately 15% of revenue. The company is also exploring clinical trials in French clinics to study the combination of the Allurion Balloon with GLP-1s, aiming to address muscle mass loss during obesity treatment.
In France, approximately 47% of the population has excess weight, with 17% classified as obese. While GLP-1 therapies have shown to reduce lean mass by about 40% of total weight lost, previous studies of the Allurion Balloon combined with Virtual Care Suite demonstrated that patients can lose weight while maintaining or increasing muscle mass. In one study of 571 patients, subjects gained 5.6% in lean body mass while losing 14% of total body weight over four months. Another study with 167 patients showed a 15.7% weight reduction with no muscle mass loss.
Allurion Technologies (NYSE: ALUR) has announced a registered direct offering of 1,240,000 shares of common stock priced at $6.00 per share, aiming to raise approximately $7.4 million in gross proceeds. The offering is priced at-the-market under NYSE rules.
In a concurrent private placement, the company will issue warrants to purchase up to 1,240,000 additional shares at an exercise price of $6.00 per share. These warrants will become exercisable immediately following stockholder approval and will expire five years after such approval. The company also agreed to reprice its outstanding warrants from July 2024 to $6.00 per share for existing warrant holders participating in this offering.
Roth Capital Partners is serving as the exclusive placement agent. The offering is expected to close around January 27, 2025. The proceeds will be used for working capital and general corporate purposes.
Allurion Technologies (NYSE: ALUR) has announced plans to start a clinical study combining its Allurion Program with GLP-1 agonists to optimize muscle mass during weight loss treatment. The initiative addresses a significant concern with GLP-1 therapy, which has shown approximately 40% reduction in lean mass as a proportion of total weight lost.
Previous studies of the Allurion Balloon combined with their Virtual Care Suite have demonstrated promising results: In a study of 571 patients, participants gained 5.6% in lean body mass while losing 14% of total body weight over four months. Another study with 167 patients showed a 15.7% weight reduction with no muscle mass loss.
The company aims to prove that combining their balloon technology with GLP-1 therapy could become the gold standard for obesity care by enabling significant weight loss while improving muscle mass and body composition.
Allurion Technologies (NYSE: ALUR) announced the issuance of a new U.S. patent for their next-generation weight loss device. The U.S. Patent No. 12,209,677, titled “Binary Fluid Control Valve System,” was issued on January 15, 2025. This patent covers enhanced claims for Allurion's proprietary Balloon technology, specifically focusing on the precision of its valve system. The patent provides protection through July 2039. This addition brings Allurion's patent portfolio to 20 U.S. patents and 59 global patents.
The Allurion Program combines the Allurion Gastric Balloon, a swallowable and procedure-less gastric balloon, with the Allurion Virtual Care Suite, including a mobile app, connected scale, and Allurion Insights for healthcare providers. Patients using the Allurion Program typically lose 10-15% of their total body weight and can increase muscle mass in some cases.
Shantanu Gaur, Allurion’s Founder and CEO, emphasized that the new patent strengthens their global patent portfolio, reflecting the innovation and effectiveness of their weight loss solutions.